Latest Articles

Publication Date
All News Scientific
Acrivon Therapeutics COO Devroe buys $17k in shares - Investing.com

Acrivon Therapeutics COO Devroe buys $17k in shares Investing.com

Published: Jan. 15, 2026, 11:55 p.m.
Read Full Article
Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan - Defense World

Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan Defense World

Published: Jan. 10, 2026, 6:12 a.m.
Read Full Article
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com UK

Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com UK

Published: Jan. 9, 2026, 2:25 p.m.
Read Full Article
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com

Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com

Published: Jan. 9, 2026, 1:59 p.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 9, 2026, 6:18 a.m.
Read Full Article
Why Is Acrivon Therapeutics Stock Falling Today? - Acrivon Therapeutics (NASDAQ:ACRV) - Benzinga

Why Is Acrivon Therapeutics Stock Falling Today? - Acrivon Therapeutics (NASDAQ:ACRV) Benzinga

Published: Jan. 8, 2026, 7:02 p.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - The Manila Times

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 8, 2026, 12:53 p.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b - GlobeNewswire

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b GlobeNewswire

Published: Jan. 8, 2026, 12:30 p.m.
Read Full Article
The interplay of microbiome, molecular mechanisms, and fertility -an integrated review.

The human microbiome, particularly the gut and reproductive tract microbiota, plays a critical role in regulating fertility through complex molecular and immunological mechanisms. This review synthesizes emerging evidence on the …

Published: Dec. 26, 2025, midnight
Read Full Article
Dysbiosis Gut-reproductive axis Infertility Microbial metabolites Microbiome therapeutics
Onconic Therapeutics wins IND approval for phase 1b–2 gastric cancer trial in Korea - CHOSUNBIZ - Chosunbiz

Onconic Therapeutics wins IND approval for phase 1b–2 gastric cancer trial in Korea - CHOSUNBIZ Chosunbiz

Published: Dec. 17, 2025, 1:04 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!